Changing treatment landscapes, new challenges for hemonc pharmacists
Susannah Koontz Webb
What are the advantages of using histamine dihydrochloride together with immunotherapy?
Exciting results for frontline ibrutinib plus FCR for younger CLL patients
Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status
An overview of iwNHL 2016 by Prof. Anas Younes